Tyra Biosciences (TYRA) Cash from Operations (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Cash from Operations came in at 32571000.0 in Q1 2026, down 27.94% YoY from 45199919.22 in Q1 2025, and down 37.87% on a QoQ basis from 23624000.0 in Q4 2025.
Tyra Biosciences (TYRA) Cash from Operations (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Cash from Operations data on file, last reported at 32571000.0 in Q1 2026.
- Quarterly Cash from Operations fell 27.94% year-over-year to 32571000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 102255000.0 (down 39.68% YoY) and the FY2025 annual result came in at 95142000.0, down 36.36% from the prior year.
- Cash from Operations slipped to 32571000.0 in Q1 2026, from 23624000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 8925000.0 in Q1 2022 to a low of 32571000.0 in Q1 2026.
- A 5-year average of 17524176.47 and a median of 17168000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 284.85% — and 2023, when it surged 43.99%.
- Tracing TYRA's Cash from Operations over 5 years: stood at 11980000.0 in 2022, then retreated by 12.95% to 13532000.0 in 2023, then tumbled by 44.77% to 19590000.0 in 2024, then slipped by 20.59% to 23624000.0 in 2025, then plunged by 37.87% to 32571000.0 in 2026.
- The last three Cash from Operations figures came in at 32571000.0 (Q1 2026), 23624000.0 (Q4 2025), and 22380000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | -31.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.08 Mn |
| Jun 30, 2026 | -31.08 Mn |
| Mar 31, 2026 | -32.57 Mn |
| Mar 31, 2026 | -32.57 Mn |
| Dec 31, 2025 | -23.62 Mn |
| Dec 31, 2025 | -23.62 Mn |
| Sep 30, 2025 | -22.38 Mn |
| Sep 30, 2025 | -22.38 Mn |
| Jun 30, 2025 | -23.68 Mn |
| Jun 30, 2025 | -23.68 Mn |
| Mar 31, 2025 | -25.46 Mn |
| Mar 31, 2025 | -25.46 Mn |
| Dec 31, 2024 | -19.59 Mn |
| Dec 31, 2024 | -19.59 Mn |
| Sep 30, 2024 | -17.90 Mn |
| Sep 30, 2024 | -17.90 Mn |
| Jun 30, 2024 | -10.26 Mn |
| Jun 30, 2024 | -10.26 Mn |
| Mar 31, 2024 | -22.03 Mn |
| Mar 31, 2024 | -22.03 Mn |